Sanofi American Depositary Receipt (SNY)
Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study
SNY's phase III LEAP2MONO study meets all primary endpoints, with venglustat improving neurological symptoms in type 3 Gaucher disease patients.
UK industry body says Sanofi in breach over RSV therapy claims against Pfizer
Sanofi has breached the UK pharma code of practice with unsubstantiated claims that its Beyfortus was more effective than Pfizer's RSV vaccine, the industry's self-regulatory body said on Monday, responding to a complaint.
Sanofi's genetic disorder drug shows mixed results in late-stage trials
French drugmaker Sanofi said on Monday that its experimental genetic disorder treatment showed promise in a late-stage study of patients with a type of Gaucher disease, but failed to meet the main goal in a separate trial.
Sanofi Beats on Q4 Earnings, Expects Profitable Growth in 2026
Sanofi SNY reported fourth-quarter 2025 adjusted earnings of 89 cents per American depositary share, which beat the Zacks Consensus Estimate of 84 cents. Earnings of €1.53 per share rose 16.8% on a reported basis and 26.7% on a constant currency rate (“CER”) basis, driven by cost control.
Sanofi to Launch $1.20 Billion Share Buyback
The buyback comes as the French drugmaker said that its sales and earnings for the fourth quarter rose.
Sanofi Says Its Amlitelimab Drug Showed Promising Results in Treating Eczema
Sanofi said its amlitelimab drug confirmed its potential to treat eczema in patients 12 years and older in two late-phase studies.
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes
SNY wins EU approval for Teizeild, the first disease-modifying drug to delay stage 3 type 1 diabetes in adults and children aged eight and older.
FDA Accepts SNY Filing for Expanded Use of T1D Drug in Young Children
Sanofi wins FDA priority review to expand Tzield's use to children as young as one, aiming to delay type 1 diabetes progression.
Sanofi Says FDA Agrees to Review Diabetes Drug Age Range
The company said the regulator accepted a priority review to potentially expand the current age range for its Tzield type-1 diabetes drug to include children as young as one year old.
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise
SNY's $2.2 billion deal for Dynavax adds Heplisav-B, a shingles candidate, and other vaccine programs, strengthening its adult vaccine franchise and pipeline.
Sanofi to acquire Dynavax in $2.2B Deal to boost adult vaccines
French pharmaceutical giant Sanofi SA said on Wednesday it has agreed to acquire US-based vaccines company Dynavax Technologies Corp in a $2.2 billion deal, strengthening its presence in the adult immunization market. Under the agreement, Sanofi will launch a cash tender offer of $15.50 per Dynavax share, representing a 39% premium to the company's pre-deal stock price.
Sanofi to acquire US biotech Dynavax for $2.2 billion
French drugmaker Sanofi has entered into an agreement to acquire U.S. vaccines company Dynavax Technologies Corporation for around $2.2 billion (1.87 billion euros), it said on Wednesday.
